GlassScriptPhysician profile
Lisa Moore
NPI 1730240326
$972.53
in general payments reported to CMS, 2019-2025
24 companies · $560 in 2025
The $560 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $13.09 · 2023: $26.67 · 2024: $258 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $156.03 | 2021-2025 | |
| Ibsa Pharma INC. | $90.86 | 2024-2025 | Licart, Tirosint, Flector |
| Corcept Therapeutics | $78.88 | 2024-2025 | Korlym |
| Lundbeck LLC | $67.24 | 2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $61.73 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tg Therapeutics, INC. | $50.16 | 2025 | |
| Merz North America, INC. | $46.70 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $40.66 | 2024-2025 | Airsupra |
| Aimmune Therapeutics, INC. | $38.85 | 2024-2025 | Zenpep |
| Genentech USA, INC. | $33.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.38 | 2021 | |
| Dexcom, INC. | $30.35 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $27.45 | 2025 | Sunosi |
| Boston Scientific Corporation | $27.42 | 2021-2022 | |
| Corium, LLC | $25.95 | 2025 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.61 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $22.48 | 2025 | Quviviq |
| Pfizer INC. | $20.46 | 2024 | |
| Amgen INC. | $19.02 | 2025 | Evenity, Prolia |
| Lilly USA, LLC | $17.75 | 2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $17.33 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $16.05 | 2025 | Qelbree |
| Neos Therapeutics, LP | $15.41 | 2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $14.16 | 2024 | Capvaxive, Gardasil 9, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.